Jun 6 |
FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward
|
Jun 4 |
Why HealthEquity Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
|
Jun 3 |
FibroGen stock rallies 30% after hours on FG-3165, FG-3175 updates
|
Jun 3 |
FibroGen Stock Is Surging After The Bell: What's Going On?
|
Jun 3 |
FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials
|
Jun 3 |
FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors
|
Jun 3 |
FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference
|
May 28 |
7 Penny Biotech Stocks to Triple Your Investment
|
May 28 |
Pamrevlumab And Roxadustat: Evaluating FibroGen's Future Amid Financial Strains
|
May 23 |
FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncol...
|